Induction of Interferon-Stimulated Genes Correlates with Reduced Growth of Influenza A Virus in Lungs after RIG-I Agonist Treatment of Ferrets

• Published in: Journal of virology 2022-08, Vol.96 (16), p.e0055922-e0055922
• Main Authors: Schwab, Lara S U, Londrigan, Sarah L, Brooks, Andrew G, Hurt, Aeron C, Sahu, Anshupa, Deng, Yi-Mo, Moselen, Jean, Coch, Christoph, Zillinger, Thomas, Hartmann, Gunther, Reading, Patrick C
• Format: Article
• Language: English
• Subjects: Animals; Antiviral Agents - pharmacology; Ferrets - metabolism; Humans; Immunity, Innate; Influenza A virus - genetics; Influenza, Human; Interferons - metabolism; Leukocytes, Mononuclear - metabolism; Lung; Mice; Vaccines and Antiviral Agents; Virology; Virus Replication - genetics
• ISSN: 0022-538X; 1098-5514
• DOI: 10.1128/jvi.00559-22

Intracellular RIG-I receptors represent key innate sensors of RNA virus infection, and RIG-I activation results in the induction of hundreds of host effector genes, including interferon-stimulated genes (ISGs). Synthetic RNA agonists targeting RIG-I have shown promise as antivirals against a broad spectrum of viruses, including influenza A virus (IAV), in both and mouse models of infection. Herein, we demonstrate that treatment of a ferret airway epithelial (FRL) cell line with a RIG-I agonist rapidly and potently induced expression of a broad range of ISGs and resulted in potent inhibition of growth of different IAV strains. In ferrets, a single intravenous injection of RIG-I agonist was associated with upregulated ISG expression in peripheral blood mononuclear cells and lung tissue, but not in nasal tissues. In a ferret model of viral contact transmission, a single treatment of recipient animals 24 h prior to cohousing with IAV-infected donors did not reduce virus transmission and shedding but did result in reduced lung virus titers 6 days after treatment. A single treatment of the IAV-infected donor animals also resulted in reduced virus titers in the lungs 2 days later. Thus, a single intravenous treatment with RIG-I agonist prior to infection or to ferrets with an established IAV infection can reduce virus growth in the lungs. These findings support further development of RIG-I agonists as effective antiviral treatments to limit the impact of IAV infections, particularly in reducing virus replication in the lower airways. RIG-I agonists have shown potential as broad-spectrum antivirals and in mouse models of infection. However, their antiviral potential has not been reported in outbred animals such as ferrets, which are widely regarded as the gold standard small animal model for human IAV infections. Herein, we demonstrate that RIG-I agonist treatment of a ferret airway cell line resulted in ISG induction and inhibition of a broad range of human influenza viruses. A single intravenous treatment of ferrets also resulted in systemic induction of ISGs, including in lung tissue, and when delivered to animals prior to IAV exposure or to animals with established IAV infection treatment resulted in reduced virus replication in the lungs. These data demonstrate the effectiveness of single RIG-I treatment against IAV in the ferret model and highlight the importance of future studies to optimize treatment regimens and delivery routes to maximize their ability t